

REMARKS

Claims 1-14, 16-17, and 20-22 are pending in the application before entry of this amendment. By way of this amendment, Claims 1, 2, 12, and 13 have been amended, claims 10, 16, 17, 21, and 22 have been canceled, and Claims 23-40 have been newly added.

Rejection under 35 USC 112, 2nd Paragraph

Claims 1-10 and 12-22 are rejected as being indefinite. The claims have been amended to overcome the rejections.

Claims 1 and 2 have been amended to further define the recited 5 and 6-membered heteroaryls. Applicants submit that the added recitation specifically describes the disclosed heteroaryls from page 2, line 20 to page 3, line 5, of the originally-filed specification.

The Examiner questions the “*” used in claim 1, and indicates that “*” is normally used to indicate a chiral center. Indeed, the “*” is used to indicate a chiral center (see page 3, ll. 11-13). No amendment has been made to the recitation of B, since the “*” is used in the claim as conventionally understood in the art.

Claim 10 has been canceled, thereby obviating the rejection of claim 10.

Claims 12 and 13 have been amended to clarify the processes recited in the claims. Support for the amendments to claims 12 and 13 are provided on page 13, line 17 to the bottom of page 15, and page 17, line 18 to page 18, line 13, of the originally-filed specification.

Rejection under 35 USC 112, 1st Paragraph


Claims 15, 17, 21, and 22 are rejected under 35 USC 112, 1st paragraph as being non-enabled. Applicants presume that the rejection of claim 15 was intended to be directed at claim 16, and the arguments below are made accordingly.

Claims 16, 17, 21, and 22 are canceled herein. New claims 23-40 have been added. The claims are supported by pages 7-9 of the originally-filed specification. No new matter has been added. Applicants submit that the cancellation of claims 16, 17, 21, and 22 obviate the rejection under 35 USC 112, 1st paragraph.

Conclusion

Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8160, to discuss this case, if desired.

Respectfully submitted,



J. Scott Young
Attorney for Applicants
Reg. No. 45,582

Date: 9 Mar 2006
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
(919) 483-8160
fax: (919) 483-7988
Scott.S.Young@GSK.com